LONDON (Alliance News) - Sareum Holdings PLC said Thursday that information on its clinical development candidate CCT245737, which it discovered in a collaboration with the Institute of Cancer Research in London and Cancer Research Technology, has been publishing in medical journal Oncotarget.
The information in the journal describes how CCT245737 can be used to boost the effectiveness of convention chemotherapies, and could be used to treat lung and pancreatic cancers.
"The publication of CCT245737 data in this high-impact journal will bring what we believe to be a best-in-class drug candidate to the attention of our peers and potential licence partners. We are extremely encouraged by the wide ranging potential use for our CHK1 inhibitor either as a single agent or when dosed in combination with other chemotherapies. The preclinical studies are progressing well and we look forward to providing an update with our final results," said Chief Executive Officer Tim Mitchell in a statement.
Shares in Sareum are trading up 7.7% at 0.264 pence Thursday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Sareum (SAR)